Sarepta hikes forecast for Duchenne muscular dystrophy drug sales … – Boston Business Journal

Posted: Published on April 28th, 2017

This post was added by Alex Diaz-Granados


Boston Business Journal
Sarepta hikes forecast for Duchenne muscular dystrophy drug sales ...
Boston Business Journal
Sarepta Therapeutics CEO Ed Kaye said Thursday that he plans to step down from his post at the Cambridge biotech at the end of the year. Kaye, who was ...

and more »

Continue reading here:
Sarepta hikes forecast for Duchenne muscular dystrophy drug sales ... - Boston Business Journal

Related Posts
This entry was posted in Muscular Dystrophy Treatment. Bookmark the permalink.

Comments are closed.